Duvelisib

Verastem Inc (NASDAQ: VSTM) shares gained 20 percent Monday morning and traded above the $7 per share mark for the first time since 2015 in reaction to an encouraging presentation delivered over the weekend. What Happened Versatem presented encouraging results from its lead candidate...

Verastem Inc (NASDAQ: VSTM) stock had a relatively flat month in June despite the firm’s presentation of positive follow-up data for its DYNAMO study of Duvelisib, its PI3K-delta and gamma inhibitor for patients with follicular lymphoma (FL), small lymphocytic lymphoma (SLL), and marginal...

Verastem Inc (NASDAQ: VSTM) is a biopharmaceutical company that focuses on discovering and developing therapies for the treatment of patients with cancer. Verastem acquired a license agreement from Infinity Pharmaceuticals granting Verastem exclusive worldwide rights to develop and...

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) released the initial data for Duvelisib on June 15, which were below expectations. Morgan Stanley’s Matthew Harrison downgraded the rating on the company from Overweight to Equal Weight, while lowering the price target from $11 to $1. Harrison...